Heart Failure CE/CME ACCREDITED Watch Time: 35 mins

touchPANEL DISCUSSION Aiming for improved outcomes in HFrEF: Patient education, evidence-based treatment and biomarkers

Watch a panel of experts discuss strategies to support patients following a diagnosis of heart failure with reduced ejection fraction (HFrEF), implementing evidence-based therapies into clinical practice and the role of biomarkers in patient management.

Prof. Piotr Ponikowski

Wrocław Medical University, Wrocław, Poland

CHAIR

Panelists:

Prof. Adriaan Voors, Dr Stephen Greene

Video Chapters

Introduction

Prof. Piotr Ponikowski introduces the panel of leading experts in heart failure and outlines the agenda for discussion on patient support, evidence-based therapies and biomarkers in HFrEF.

view bio and disclosures 1/4 Next Chapter

How can we help patients navigate their journey after a diagnosis of HFrEF?

The panel discusses the patient journey with HFrEF, including key challenges, patient education and the potential impact of treatment changes on clinical outcomes.

view bio and disclosures 2/4 Next Chapter

How can we implement evidence-based therapies for HFrEF into clinical practice?

The panel considers the unmet needs in the management of HFrEF and reviews new treatment approaches.

view bio and disclosures 3/4 Next Chapter

What are the current and prospective roles of HFrEF biomarkers for guiding patient management?

The panel discusses the role of biomarkers for guiding decision-making in HFrEF.

view bio and disclosures 4/4 Take CE/CME Test

Overview & Learning Objectives

Overview

In this activity, a panel of experts discuss approaches for improving outcomes in patients with HFrEF. They consider key educational points for patients, selecting evidence-based therapies and using biomarkers to guide decision-making.

This activity is jointly provided by USF Health and touchIME.read more

Target Audience

This activity has been designed to meet the educational needs of cardiologists, primary care physicians and heart failure nurse specialists involved in the management of heart failure.

Disclosures

All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

Faculty

Prof. Piotr Ponikowski discloses: Advisory board or panel fees from: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Impulse Dynamics, Merck Sharp & Dohme, Novartis and Vifor Pharma. Speaker’s bureau fees from: AstraZeneca, Boehringer Ingelheim, Impulse Dynamics, Novartis, and Vifor Pharma. Research grants from: Vifor Pharma.

Prof. Adriaan Voors discloses: Consulting fees and/or research grants from: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cytokinetics, Myokardia, Merck, Novo Nordisk, Novartis and Roche Diagnostics.

Dr Stephen Greene discloses: Advisory board/consulting fees from: Amgen, AstraZeneca, Bayer, Cytokinetics, Merck and Vifor Pharma. Research support from: American Heart Association, Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, Novartis and Pfizer.

Content Reviewer

Madjid Mirzai-Tehrane, MD has no financial interests/relationships or affiliations in relation to this activity.

Touch Medical Director

Sola Neunie has no financial interests/relationships or affiliations in relation to this activity.

USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

Requirements for Successful Completion

In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

If you have questions regarding credit please contact cpdsupport@usf.edu

Accreditations

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)

Advanced Practice Providers

Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

Date of original release: 09 August 2021. Date credits expire: 09 August 2022.

If you have any questions regarding credit please contact cpdsupport@usf.edu

Learning Objectives

After watching this activity, participants should be better able to:

Describe approaches to support patients following a diagnosis of HFrEF
Use the latest data to select the most appropriate evidence-based treatment for each patient with HFrEF
Discuss the use of biomarkers to guide treatment selection and monitoring

Faculty & Disclosures

Prof. Piotr Ponikowski

Wrocław Medical University, Wrocław, Poland

Piotr Ponikowski is Professor of Cardiology, Rector and Head of Department of Heart Diseases at Wrocław Medical University. He is also Head of the Center for Heart Diseases at University Hospital, Wrocław, Poland. read more

His research interests focus on the pathophysiology and management of acute and chronic heart failure. He is a co-author of more than 700 peer-reviewed papers, with a total number of citations >95000 and an h-index of 117. Prof. Ponikowski has been recognized as a Highly Cited Researcher by Thomson Reuters in 2016, 2017, 2018 and 2019.

Prof. Ponikowski has served as a member of the Board of the European Society of Cardiology’s (ESC) Heart Failure Association (HFA). He served as President of the HFA from 2010–2012 and is the former president of the Polish Cardiac Society.

Prof. Ponikowski has been involved in the development of several guidelines on the management of cardiovascular diseases (edited by the ESC, as the member of the ESC Committee for Practice Guidelines) and was Chair of the 2016 ESC Heart Failure Guidelines.

Prof. Ponikowski is a member of editorial boards for several cardiology-focused journals. He has been a member of international steering/executive committees and endpoint committees for numerous clinical trials.

Prof. Adriaan Voors

University Medical Center Groningen, Groningen, The Netherlands

Adriaan Voors is Professor of Cardiology and specializes in heart failure at the University Medical Centre Groningen, The Netherlands. read more

Prof. Voors has been Established Clinical Investigator of the Netherlands Heart Foundation since 2007 and is currently Director of the Heart Failure Clinic of the Department of Cardiology at the University Medical Center Groningen.

Prof. Voors has supervised 40 PhD students, mainly on heart failure-related topics. He is an editorial board member of the European Journal of Heart Failure, Clinical Research in Cardiology, Cardiovascular Drugs and Therapy, the Journal of Cardiovascular Medicine and Heart Failure Reviews. He has been involved in 49 clinical trials for novel therapies in acute and chronic heart failure, as either the principal investigator or an executive/steering committee member.

Prof. Voors was a member of the 2012 ESC Heart Failure Guidelines Committee, and Co-Chair of the 2016 ESC Heart Failure Guidelines. He has authored 640 peer-reviewed papers and several books and chapters. His h-index is 90.

Dr Stephen Greene

Duke University, Durham, NC, USA

Stephen Greene is a cardiologist and Assistant Professor of Medicine in the Division of Cardiology and Duke Clinical Research Institute, at the Duke University School of Medicine. read more

Dr Greene specializes in caring for patients with heart failure, including patients who are best treated with medications and patients who receive advanced therapies, including left ventricular assist devices and heart transplants.

Dr Greene’s research focuses on improving quality of care and outcomes for patients with heart failure. He has been a collaborator and co-author of multiple national and international heart failure trials, including the ASTRONAUT, SOCRATES-Reduced and COMPOSE trials, as well as the ongoing TRANSFORM-HF trial. He has led multiple analyses from national registries, characterizing the quality of heart failure treatment in routine clinical practice, including studies leveraging the American Heart Association’s Get With The Guidelines Heart Failure registry, the CHAMP-HF registry and the VICTORIA registry.

Dr Greene’s collaborative work has led to more than 185 publications in peer-reviewed journals.